- Analysts at Citi say Philips' (PHG) recent agreement with the U.S. Food and Drug Administration will likely be positive for Australia's ResMed (RMD)(RMD)
- Philips agreed with the U.S. Department of Justice on the terms of a consent decree under which the Dutch health tech company will not sell sleep and respiratory devices in the U.S. until the requirements are met
- Citi expects this to be a catalyst for RMD's earnings and sees its compound annual revenue growth rate of 5% over FY23-FY26
- Brokerage retains "buy" rating on RMD with PT at A$34
- 12 of 13 analysts rate stock "buy" or higher, one "hold"; median PT is A$32.31
Analysts at Citi say Philips' (PHG) recent agreement with the...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.73 |
Change
0.060(0.19%) |
Mkt cap ! $20.14B | |||
| Open | High | Low | Value | Volume |
| $31.81 | $31.89 | $31.62 | $25.45M | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6917 | $31.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.77 | 4586 | 1 |
View Market Depth
| Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$31.81 |
Change
0.060 ( 0.35 %) |
||||
| Open | High | Low | Volume | ||
| $31.73 | $31.84 | $31.62 | 459538 | ||
| Last updated 15.59pm 12/06/2024 ? | |||||
| RMD (ASX) Chart |